Lowest Price Guaranteed From USD 4,899
Published
October 2020
Pages
184
View Count
5243
Example Insights
Report Description
Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies. However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination. Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.
Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality. Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.
The “Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill / Finish, Cryopreservation, Thawing, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial organizations), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the automated and closed cell therapy processing systems market and its likely evolution in the short-mid-term and long term.
Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of products. It features a detailed discussion on the key challenges associated with currently adopted cell therapy manufacturing approaches. The chapter also highlights the role of automation in cell therapy manufacturing, providing details on the key advantages and challenges associated with such systems. Further, it features a discussion on the key growth drivers and roadblocks related to the use of such systems, as well as certain trends that the domain is expected to witness in the coming years.
Chapter 4 provides an overview of the automated and closed cell therapy processing systems landscape. It includes information on more than 60 automated and closed systems that are currently being used for processing the cell therapies. It features detailed information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert systems), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification / validation, maintenance, regulatory support and others), regulatory certification / accreditations obtained (GMP / cGMP, GAMP, GCP, GTP / cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).
Chapter 5 presents a detailed competitiveness analysis of automated and closed cell therapy processing systems based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 6 presents detailed profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
Chapter 7 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, during the period 2016-2020. It provides a brief description on the various types of partnership models adopted (including asset purchase agreement, distribution agreement, joint venture, merger / acquisition, product commercialization agreement, product development agreement, product development and commercialization agreement, product evaluation agreement, product integration agreement, product utilization agreement, research agreement and others) by stakeholders in this domain. Further, it includes analyses based on the year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner’s focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.
Chapter 8 highlights the recent initiatives undertaken by big pharma players in the automated and closed cell therapy processing systems domain.
Chapter 9 features a list of more than 300 cell therapy developers and manufacturers that are anticipated to partner with automated and closed cell therapy processing system providers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company’s size and its experience in this field), company’s pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), type of culture used (adherent or suspension) and type of technology (automated systems or closed systems).
Chapter 10 presents a case study, highlighting the differences in cost associated with manufacturing of cell therapies using manual, partially automated and bespoke automated and closed systems, across various process operations.
Chapter 11 presents a detailed market forecast analysis, highlighting the likely growth of the automated and closed cell therapy processing systems market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America).
Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis), and Jean Sebastien Parisse (Commercial Director, Aseptic Technologies).
Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
4.2.1. Analysis by Cell Processing Step
4.2.2. Analysis by Types of Cells
4.2.3. Analysis by Type of Culture
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Key Features
4.2.6. Analysis by Application Area
4.2.7. Analysis by Regulatory Certifications / Accreditations
4.2.8. Analysis by End User
4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Support Service(s) Offered
4.3.4. Analysis by Location of Headquarters
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis
5.4.1. Automated and Closed Cell Processing Systems for Apheresis
5.4.2. Automated and Closed Cell Processing Systems for Separation
5.4.3. Automated and Closed Cell Processing Systems for Expansion
5.4.4. Automated and Closed Cell Processing Systems for Harvest
5.4.5. Automated and Closed Cell Processing Systems for Fill Finish
5.4.6. Automated and Closed Cell Processing Systems for Cryopreservation
5.4.7. Automated and Closed Cell Processing Systems for Thawing
6. COMPANY PROFILES
6.1 Chapter Overview
6.2 Cytiva
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Pall
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Terumo BCT
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook
6.5 ThermoGenesis
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook
7. PARTNERSHIPS
7.1 Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Therapy
7.3.4. Analysis by Cell Processing Step
7.3.5. Analysis by Type of Automated and Closed Cell Processing Systems
7.3.6. Analysis by Partner’s Focus Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Country-Wise Distribution
7.3.8.2. Intercontinental and Intracontinental Agreements
8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN
8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
8.2.1. Initiatives Undertaken by AbbVie
8.2.2. Initiatives Undertaken by Bristol Myers Squibb
8.2.3. Initiatives Undertaken by Gilead Sciences
8.2.4. Initiatives Undertaken by GlaxoSmithKline
8.2.5. Initiatives Undertaken by Johnson & Johnson
8.2.6. Initiatives Undertaken by Novartis
8.2.7. Initiatives Undertaken by Roche
8.2.8. Initiatives Undertaken by Sanofi
8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
8.2.10. Summary of Big Pharma Initiatives
9. LIKELY PARTNER
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
9.3.1. Dendritic Cell Therapy
9.3.2. Stem Cell Therapy
9.3.3. T-cell Therapy
9.3.4. Natural Killer Cell Therapy
9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
9.4.1. Dendritic Cell Therapy
9.4.2. Stem Cell Therapy,
9.4.3. T-cell Therapy
9.4.4. Natural Killer Cell Therapy
10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS
10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah®
10.4. Likely Cost Saving Potential for Yescarata®
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030
11.3.1. Overall Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step
11.3.1.1. Automated and Closed Cell Therapy Processing Systems Market for Apheresis, 2020-2030
11.3.1.2. Automated and Closed Cell Therapy Processing Systems Market for Separation, 2020-2030
11.3.1.3. Automated and Closed Cell Therapy Processing Systems Market for Expansion, 2020-2030
11.3.1.4. Automated and Closed Cell Therapy Processing Systems Market for Harvest, 2020-2030
11.3.1.5. Automated and Closed Cell Therapy Processing Systems Market for Fill / Finish, 2020-2030
11.3.1.6. Automated and Closed Cell Therapy Processing Systems Market for Cryopreservation, 2020-2030
11.3.1.7. Automated and Closed Cell Therapy Processing Systems Market for Thawing, 2020-2030
11.3.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation
11.3.2.1. Automated and Closed Cell Therapy Processing Systems Market for Pre-clinical / Clinical Operations, 2020-2030
11.3.2.2. Automated and Closed Cell Therapy Processing Systems Market for Commercial Operations, 2020-2030
11.3.3. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User
11.3.3.1. Automated and Closed Cell Therapy Processing Systems Market for Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030
11.3.3.2. Automated and Closed Cell Therapy Processing Systems Market for Cell Therapy Manufacturers / Developers, 2020-2030
11.3.4. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographic Regions
11.3.4.1. Automated and Closed Cell Therapy Processing Systems Market in North America, 2020-2030
11.3.4.2. Automated and Closed Cell Therapy Processing Systems Market in Europe, 2020-2030
11.3.4.3. Automated and Closed Cell Therapy Processing Systems Market in Asia-Pacific, 2020-2030
11.3.4.4. Automated and Closed Cell Therapy Processing Systems Market in Latin America (LATAM), 2020-2030
11.3.4.5. Automated and Closed Cell Therapy Processing Systems Market in Middle East North America (MENA), 2020-2030
12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways
13. INTERVIEW / SURVEY TRANSCRIPT(S)
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
Figure 3.1. Key Steps Involved in Manufacturing of Cell Therapies
Figure 3.2. Key Considerations while Automating Cell Therapy Manufacturing Process
Figure 3.3. Role of Automated and Closed Systems across Each Cell Therapy Processing Step
Figure 3.4. Advantages offered by Automated and Closed Cell Processing Systems
Figure 3.5. Challenges Associated with Automated and Closed Cell Processing Systems
Figure 3.6. Growth Drivers and Roadblocks in the Automated and Closed Systems Market
Figure 4.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Figure 4.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Figure 4.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Figure 4.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Figure 4.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Figure 4.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Figure 4.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Figure 4.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Figure 4.9. Automated and Closed Cell Therapy Processing System Providers: Distribution by Year of Establishment
Figure 4.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Figure 4.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Figure 4.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Figure 4.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Figure 4.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Figure 5.1. Product Competitiveness Analysis: Automated and Closed Systems for Cell Apheresis
Figure 5.2. Product Competitiveness Analysis: Automated and Closed Systems for Cell Separation
Figure 5.3. Product Competitiveness Analysis: Automated and Closed Systems for Cell Expansion
Figure 5.4. Product Competitiveness Analysis: Automated and Closed Systems for Cell Harvesting
Figure 5.5. Product Competitiveness Analysis: Automated and Closed Systems for Fill Finish
Figure 5.6. Product Competitiveness Analysis: Automated and Closed Systems for Cryopreservation
Figure 5.7. Product Competitiveness Analysis: Automated and Closed Systems for Thawing
Figure 6.1. Terumo BCT: Annual Revenues, FY 2016 – FY 2020
Figure 6.2. ThermoGenesis: Annual Revenues, FY 2016 – FY 2020
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Figure 7.4. Recent Partnerships: Distribution by Type of Therapy
Figure 7.5. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Figure 7.6. Recent Partnerships: Distribution by Cell Processing Step
Figure 7.7. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Figure 7.8. Recent Partnerships: Distribution by Type of Partner
Figure 7.9. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Figure 7.10. Recent Partnerships: Most Active Players
Figure 7.11. Recent Partnerships: Country-Wise Distribution
Figure 7.12. Recent Partnerships: Intercontinental and Intracontinental Distribution
Figure 8.1. Big Pharma Initiatives Summary
Figure 10.1. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
Figure 10.2. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Figure 10.3. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Figure 11.1. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
Figure 11.2. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
Figure 11.3. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
Figure 11.4. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
Figure 11.5. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
Figure 11.6. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
Figure 11.7. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
Figure 11.8. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
Figure 11.9. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
Figure 11.10. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
Figure 11.11. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Figure 11.12. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
Figure 11.13. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
Figure 11.14. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
Figure 11.16. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
Figure 11.17. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Figure 11.18. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
Figure 11.19. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
Figure 11.20. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
Figure 11.21. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
Figure 11.22. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)
Table 3.1. Cell and Advanced Therapies: Key Applications
Table 3.2. Assessment of Key Cell Therapy Manufacturing Steps
Table 4.1. List of Automated and Closed Cell Therapy Processing Systems: Information on Cell Processing Step
Table 4.2. List of Automated and Closed Cell Therapy Processing Systems: Information on Types of Cells
Table 4.3. List of Automated and Closed Cell Therapy Processing Systems: Information on Type of Culture
Table 4.4. List of Automated and Closed Cell Therapy Processing Systems: Information on Scale of Operation
Table 4.5. List of Automated and Closed Cell Therapy Processing Systems: Information on Key Features
Table 4.6. List of Automated and Closed Cell Therapy Processing Systems: Information on Application Area
Table 4.7. List of Automated and Closed Cell Therapy Processing Systems: Information on Regulatory Certifications / Accreditations Obtained
Table 4.8. List of Automated and Closed Cell Therapy Processing Systems: Information on End Users
Table 4.9. List of Automated and Closed Cell Therapy Processing System Providers
Table 4.10. List of Automated and Closed Cell Therapy Processing System Providers: Information on Type of Support Service(s) Offered
Table 6.1. Cytiva: Key Highlights
Table 6.2. Cytiva: Product Portfolio
Table 6.3. Pall: Key Highlights
Table 6.4. Pall: Product Portfolio
Table 6.5. Terumo BCT: Key Highlights
Table 6.6. Terumo BCT: Product Portfolio
Table 6.7. Terumo BCT: Recent Developments and Future Outlook
Table 6.8. ThermoGenesis: Key Highlights
Table 6.9. ThermoGenesis: Product Portfolio
Table 6.10. ThermoGenesis: Recent Developments and Future Outlook
Table 7.1. Automated and Closed Cell Processing Systems: List of Partnerships, 2016-2020
Table 8.1. Automated and Closed Cell Processing Systems: List of Big Pharma Players
Table 9.1. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Developers
Table 9.2. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Developers
Table 9.3. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Developers
Table 9.4. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Developers
Table 9.5. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Dendritic Cell Therapy Manufacturers
Table 9.6. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Stem Cell Therapy Manufacturers
Table 9.7. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: T-cell Therapy Manufacturers
Table 9.8. Likely Partners for Automated and Closed Cell Therapy Processing System Providers: Natural Killer Cell Therapy Manufacturers
Table 10.1. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems, 2020-2030
Table 10.2. Cost Saving Potential of Fully Automated Systems
Table 14.1. Automated and Closed Cell Therapy Processing Systems: Distribution by Cell Processing Step
Table 14.2. Automated and Closed Cell Therapy Processing Systems: Distribution by Types of Cells
Table 14.3. Automated and Closed Cell Therapy Processing Systems: Distribution by Type of Culture
Table 14.4. Automated and Closed Cell Therapy Processing Systems: Distribution by Scale of Operation
Table 14.5. Automated and Closed Cell Therapy Processing Systems: Distribution by Key Features
Table 14.6. Automated and Closed Cell Therapy Processing Systems: Distribution by Application Area
Table 14.7. Automated and Closed Cell Therapy Processing Systems: Distribution by Regulatory Certifications / Accreditations
Table 14.8. Automated and Closed Cell Therapy Processing Systems: Distribution by End Users
Table 14.9. Automated and Closed Cell Therapy Processing System Providers: Distribution Year of Establishment
Table 14.10. Automated and Closed Cell Therapy Processing System Providers: Distribution by Company Size
Table 14.11. Automated and Closed Cell Therapy Processing System Providers: Distribution by Type of Support Services Offered
Table 14.12. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location
Table 14.13. Automated and Closed Cell Therapy Processing System Providers: Distribution by Geographical Location (Country-Wise)
Table 14.14. Leading Developers: Distribution by Number of Automated and Closed Cell Therapy Processing Systems
Table 14.15. Terumo BCT: Annual Revenues, FY 2016-FY 2020
Table 14.16. ThermoGenesis: Annual Revenues, FY 2016 – FY 2020
Table 14.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 14.18. Recent Partnerships: Distribution by Type of Partnership Model Adopted
Table 14.19. Recent Partnerships: Year-wise Trend by Type of Partnership Model Adopted
Table 14.20. Recent Partnerships: Distribution by Type of Therapy
Table 14.21. Recent Partnerships: Distribution by Type of Therapy and Type of Partnership Model Adopted
Table 14.22. Recent Partnerships: Distribution by Cell Processing Step
Table 14.23. Recent Partnerships: Distribution by Automated and Closed Cell Processing System
Table 14.24. Recent Partnerships: Distribution by Type of Partner
Table 14.25. Recent Partnerships: Distribution by Type of Cell Processing Step and Developer
Table 14.26. Recent Partnerships: Most Active Players
Table 14.27. Recent Partnerships: Country-Wise Distribution
Table 14.28. Recent Partnerships: Intercontinental and Intracontinental Distribution
Table 14.29. Big Pharma Initiatives Summary
Table 14.30. Cost Saving Analysis: Comparative Analysis of Manual, Partially Automated and Fully Automated Processing Systems, 2020-2030
Table 14.31. Cost Saving Potential of Fully Automated Processing Systems Based on Number of Patients
Table 14.32. Cost Saving Potential of Fully Automated Processing Systems Across Different Regions
Table 14.33. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030 (USD Million)
Table 14.34. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Cell Therapy Processing Step, 2020, 2025 and 2030 (USD Million)
Table 14.35. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Apheresis Systems, 2020-2030 (USD Million)
Table 14.36. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Separation Systems, 2020-2030 (USD Million)
Table 14.37. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Expansion Systems, 2020-2030 (USD Million)
Table 14.38. Automated and Closed Cell Therapy Processing Systems Market: Share of Cell Harvesting Systems, 2020-2030 (USD Million)
Table 14.39. Automated and Closed Cell Therapy Processing Systems Market: Share of Fill Finish Systems, 2020-2030 (USD Million)
Table 14.40. Automated and Closed Cell Therapy Processing Systems Market: Share of Cryopreservation Systems, 2020-2030 (USD Million)
Table 14.41. Automated and Closed Cell Therapy Processing Systems Market: Share of Thawing Systems, 2020-2030 (USD Million)
Table 14.42. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Million)
Table 14.43. Automated and Closed Cell Therapy Processing Systems Market: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Table 14.44. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Operations, 2020-2030 (USD Million)
Table 14.45. Automated and Closed Cell Therapy Processing Systems Market: Distribution by End User, 2020, 2025 and 2030 (USD Million)
Table 14.46. Automated and Closed Cell Therapy Processing Systems Market: Share of Hospitals / Medical Centers / Clinics / Research Institutes / Academic Institutes, 2020-2030 (USD Million)
Table 14.47. Automated and Closed Cell Therapy Processing Systems Market: Share of Commercial Organizations, 2020-2030 (USD Million)
Table 14.48. Automated and Closed Cell Therapy Processing Systems Market: Distribution by Key Geographical Regions, 2020, 2025 and 2030 (USD Million)
Table 14.49. Automated and Closed Cell Therapy Processing Systems Market: Share of North America, 2020-2030 (USD Million)
Table 14.50. Automated and Closed Cell Therapy Processing Systems Market: Share of Europe, 2020-2030 (USD Million)
Table 14.51. Automated and Closed Cell Therapy Processing Systems Market: Share of Asia-Pacific, 2020-2030 (USD Million)
Table 14.52. Automated and Closed Cell Therapy Processing Systems Market: Share of LATAM, 2020-2030 (USD Million)
Table 14.53. Automated and Closed Cell Therapy Processing Systems Market: Share of MENA, 2020-2030 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in the report.